1664TiP A phase II randomized study of BMS-986012, an anti-fucosyl-GM1 monoclonal antibody, plus carboplatin, etoposide, and nivolumab (NIVO) as first-line (1L) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC)

• DOI: 10.1016/j.annonc.2021.08.248
• Publication Date: 2021-09-21T18:38:09Z
• Authors: Q. Chu; K. Parikh; L. Paz-Ares; A. Navarro; B. Markman; R. Sarmiento; G. Kollia; C. He; K. Sanghavi; H. Chang; B. Fischer; U. Guha; S. Tannenbaum-Dvir; K. Wu; Y. Liu; N. Ready
• Keywords: 03 medical and health sciences; 0302 clinical medicine